North American Financial 15 Split Corp. At-The-Market Equity Program Renewed

North American Financial 15 Split Corp. renewed its at-the-market equity program, effective until November 7, 2028 unless terminated earlier. The program replaces the one established in September 2024 and permits discretionary sales of Class A and Preferred Shares at prevailing market prices through Canadian marketplaces under an October 7, 2026 agreement with National Bank Financial Inc.

Analysis

The renewal is a financing option, not evidence that capital has been raised. Its significance depends on whether shares are actually sold and at what price relative to net asset value (NAV). Class A issuance below NAV can dilute existing Class A holders; issuance above NAV can be accretive. Preferred-share issuance adds senior claims, so assess it through asset coverage and the effect on the residual value and risk borne by Class A holders—not as ordinary equity dilution. If used materially, recurring supply could also limit near-term price appreciation, although the announcement alone does not establish the program’s capacity or likely sales. The key missing inputs are the authorized issuance amount, actual sales, and contemporaneous market price versus NAV and preferred coverage. Near term, absent evidence of usage, this is a low-conviction signal. Over the next 1–3 months, sales disclosures and NAV/coverage changes matter more than the renewal itself; over the longer term, persistent issuance at unfavorable prices could compound dilution or weaken coverage. The thesis is falsified if no material issuance occurs, or if sales are consistently made at prices that are accretive without impairing preferred coverage.

Key Decisions for Investors

• No standalone directional trade on the renewal: treat it as a watch item until issuance volume and pricing are disclosed.
• For existing Class A exposure, compare the traded price with NAV and monitor any share-count growth; reassess if sales coincide with a widening discount or declining NAV per share.
• For preferred exposure, track asset coverage and any increase in senior claims; the relevant risk is deterioration in coverage, not the headline existence of an ATM.
• Do not infer a supply overhang without evidence of actual sales. Revisit the view if disclosures show sustained issuance or if market pricing moves materially below NAV.